Clinical trials: Alcohol Disorders
Essential Tremor
Clinical Trial Characterizing the Bioavailability of 1-Octanol in Adults With Ethanol-responsive Essential Tremor
OVERVIEW Essential tremor (ET) is a common movement disorder affecting 0.4% of the general population and up to 14% of people 65 years and older.
- Trial name
- NCT00102596
- Testing
- 1-Octanol
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Alcoholism
Varenicline for Alcohol Dependence
The primary objective of this study is to assess the efficacy of varenicline in reducing the proportion of heavy drinking days during the last 8 weeks of treatment in subjects with alcohol dependence confirmed by Diagnostic and…
- Trial name
- NCIG 003 (NCT01146613)
- Testing
- Varenicline
- Where
- 7 sites in United States
- Volunteers
- 200 people
- Sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Alcohol Dependence
Study of Campral (Acamprosate) for Alcohol Dependence in a Family Medicine Clinic
This is a study of a medication, acamprosate, which is an FDA approved medication for alcohol problems. We will be examining whether acamprosate compared to a sugar pill (placebo) is more effective for helping with drinking in a…
- Trial name
- NCT00381043
- Testing
- Acamprosate (Campral)
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia, Psychotic Disorders
Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
The purpose of this study is to compare the efficacy of oral risperidone (Risperdal) to risperidone long-acting (Consta) in reducing alcohol use in persons diagnosed with schizophrenia or schizoaffective disorder.
- Conditions
- Schizophrenia, Psychotic Disorders, Substance Abuse, Alcohol Abuse
- Trial name
- NCT00130923
- Testing
- Risperidone Long Acting, oral risperidone
- Where
- 8 sites in United States
- Volunteers
- 95 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Alcohol Dependence, Alcoholism
Effect of LY686017 on Alcohol Craving
This study will determine whether the experimental drug LY686017 can reduce a person's desire for alcohol. A brain chemical called Substance P acts at places in the brain called NK1 receptors.
- Trial name
- NCT00310427
- Testing
- LY686017
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Alcohol Use Disorder, Depressive Disorder
Intermittent Theta Burst for the Treatment of Alcohol Use Disorders in Veterans
The purpose of this study is to evaluate the efficacy of intermittent theta burst repetitive transcranial magnetic stimulation (iTBS) as a treatment for Veterans with an alcohol use disorder (AUD) to decrease the exceedingly high…
- Conditions
- Alcohol Use Disorder, Depressive Disorder, Cigarette Smoking
- Trial name
- NCT03291431
- Testing
- Intermittent theta burst transcranial magnetic stimulation
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Stanford University
Human Immunodeficiency Virus (HIV)
Alcohol Monitor Validation
This study will validate a wrist-worn alcohol monitor (BACtrack Skyn) in both laboratory and real-life settings.
- Trial name
- NCT03617705
- Testing
- Skyn Monitor Lab Session 1, Skyn Monitor Field Test with EMA App, Skyn Monitor Lab Session 2
- Where
- 2 sites in United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- University of Florida
Alcohol Dependence
Efficacy of Nalmefene in Patients With Alcohol Dependence
The purpose of the study is to evaluate the efficacy, safety and tolerability of nalmefene in the treatment of alcohol dependence.
- Trial name
- ESENSE1 (NCT00811720)
- Testing
- Nalmefene
- Where
- 39 sites in Austria, Finland and 2 more
- Volunteers
- 598 people
- Sponsor
- H. Lundbeck A/S
Alcohol Dependence
A Study for the Treatment of Alcohol Dependence
The Primary objective of this study is to test whether LY2196044 can reduce the number of heavy drinking days per month in people with alcohol dependence.
- Trial name
- NCT00804570
- Testing
- LY2196044
- Where
- 17 sites in United States
- Volunteers
- 375 people
- Sponsor
- Eli Lilly and Company
Alcohol Use Disorder
Effect of Allopregnanolone on Stress-induced Craving
The goal of this study is to determine whether intravenous infusion of allopregnanolone (ALLO) attenuates stress-induced craving and stress-induced anxiety in a clinical laboratory setting.
- Trial name
- NCT04015869
- Testing
- Allopregnanolone
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Yale University